SG3 Management’s Solid Biosciences SLDB Stock Holding History

SG3 Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,627	Closed	-$185K	–	1434
2020 Q4	$185K	Buy	+1,627	New	+$103K	﹤0.01%	876

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SG3 Management's SLDB Position: Q1 2021 in Review

SG3 Management sold out of Solid Biosciences (SLDB) in Q1 2021, closing a stake of 1,627 shares — an estimated $185K sold.

SG3 Management first reported a position in SLDB in Q4 2020 and held it in 1 quarter. The position peaked at $185K in Q4 2020. 104 funds tracked by Wall St. Rank hold SLDB as of Q1 2021.

SG3 Management reported no remaining Solid Biosciences position as of Q1 2021 after selling out during the quarter.
SG3 Management sold 1,627 Solid Biosciences shares in Q1 2021, an estimated $185K.
SG3 Management first reported a position in Solid Biosciences in Q4 2020 and held it in 1 quarter.
SG3 Management's Solid Biosciences position peaked at $185K in Q4 2020.
104 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2021.

Based on SG3 Management's 13F filing for Q1 2021, filed 17 May 2021.